• AAPL 169.02
  • TSLA 162.13
  • AMZN 176.59
  • MSFT 409.06
  • INTC 34.5
  • EURUSD 1.0701
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. ORYZF.PINK

Oryzon Genomics S.A (ORYZF PINK) stock market data APIs

$1.41 0(0%) as of April 23, 2024

Oryzon Genomics S.A Financial Data Overview

1.41
1.41
-
1.41
1.41
1.41-2.45
134 M
61 795 K
16 615 K
-0.04
0.638
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ORYZF',
Type: 'Common Stock',
Name: 'Oryzon Genomics S.A',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Oryzon Genomics S.A Fundamental Data is available in our Financial Data APIs

  • Net Revenue 16 615 K
  • EBITDA -20 715 964
  • Earnings Per Share -0.06
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Oryzon Genomics S.A Earnings via APIs

  • Latest Release 2023-02-17
  • EPS/Forecast -0.05

Get Oryzon Genomics S.A End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Oryzon Genomics S.A latest news via APIs

Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder

Oryzon Genomics, S.A. Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in agitation and aggression and overall disease improvement Toplin...

ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023

Oryzon Genomics, S.A. Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical tri...
Do you have any questions?
support@eodhistoricaldata.com